AVEO and Astellas announced results from their Phase 3, TIVO-1 study of tivozanib for the treatment of advanced renal cell carcinoma (RCC). TIVO-1 is a global, randomized trial evaluating the efficacy and safety of tivozanib compared to sorafenib in 517 patients with advanced RCC. Tivozanib demonstrated statistically significant improvement superiority over sorafenib in the primary endpoint of progression-free survival, with a median PFS of 11.9 months compared to a median of 9.1 months for sorafenib in the overall study population.

Tivozanib is a potent, selective, and continuous inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

For more information, call (617) 299-5000 or visit www.aveopharma.com.